IP4 Stock Overview A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
InnoCan Pharma Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for InnoCan Pharma Historical stock prices Current Share Price CA$0.12 52 Week High CA$0.24 52 Week Low CA$0.097 Beta 2.92 1 Month Change -19.46% 3 Month Change -20.79% 1 Year Change -39.21% 3 Year Change -77.10% 5 Year Change n/a Change since IPO 300.00%
Recent News & Updates InnoCan Pharma Corporation announced that it expects to receive CAD 0.7 million in funding Dec 20
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs Oct 12 InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding Aug 30
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding Aug 23
Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023) Aug 13
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center Jul 27 See more updates InnoCan Pharma Corporation announced that it expects to receive CAD 0.7 million in funding Dec 20
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs Oct 12 InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding Aug 30
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding Aug 23
Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023) Aug 13
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center Jul 27
First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023) May 28
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey May 10
Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022) Apr 02 InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding Mar 15
InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024 Mar 09 InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding Mar 06
Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022) Nov 30 InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding Oct 21
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding Sep 22
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board Sep 16
Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022) Aug 25 InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding Aug 09
New minor risk - Shareholder dilution Aug 07 InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding Aug 05
New minor risk - Shareholder dilution Jul 26 InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding Jul 26
Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology Jun 15
First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022) Jun 02
InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial May 09
Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021) Apr 02 InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding Feb 17
Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021) Nov 29
Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser Nov 19
Less than half of directors are independent Nov 16
Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy Sep 10
Second quarter 2022 earnings released Aug 31
InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology Aug 18 InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain
InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss Aug 06
Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms Jul 30
InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT Jul 07
Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management Jun 26
Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment Jun 19
Less than half of directors are independent Apr 27
InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform Mar 29
Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study Jun 25
Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers Jun 17
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment Jun 15
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study Jun 12
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study May 15
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment Mar 12
InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform Feb 24
New 90-day high: €0.33 Feb 04
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions Jan 23
New 90-day high: €0.26 Jan 19
InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes Jan 15
InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding Jan 01
New 90-day high: €0.26 Dec 29
InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA Dec 19
Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases Nov 18
Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray Oct 20
Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum Oct 16
New 90-day high: €0.23 Oct 12
Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD Oct 11 Shareholder Returns IP4 DE Pharmaceuticals DE Market 7D -14.0% -2.2% -2.0% 1Y -39.2% -15.6% 6.9%
See full shareholder returns
Return vs Market: IP4 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is IP4's price volatile compared to industry and market? IP4 volatility IP4 Average Weekly Movement 12.8% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IP4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IP4's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
Show more InnoCan Pharma Corporation Fundamentals Summary How do InnoCan Pharma's earnings and revenue compare to its market cap? IP4 fundamental statistics Market cap €35.40m Earnings (TTM ) -€2.49m Revenue (TTM ) €27.73m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IP4 income statement (TTM ) Revenue US$28.93m Cost of Revenue US$2.86m Gross Profit US$26.07m Other Expenses US$28.67m Earnings -US$2.60m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.0091 Gross Margin 90.11% Net Profit Margin -9.00% Debt/Equity Ratio 0%
How did IP4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:01 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
